Treatment outcome of switching from ranibizumab to aflibercept in patients with central retinal vein occlusion

被引：0
|
作者：
Konidaris, V.
Gorgoli, K.
Burgula, S.
Deane, J.
Banerjee, S.
Empeslidis, T.
机构：
来源：
ACTA OPHTHALMOLOGICA | 2016年 / 94卷
关键词：
D O I：
10.1111/j.1755-3768.2016.0316
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
    Pennington, Becky
    Alshreef, Abualbishr
    Flight, Laura
    Metry, Andrew
    Poku, Edith
    Hykin, Philip
    Sivaprasad, Sobha
    Prevost, A. Toby
    Vasconcelos, Joana C.
    Murphy, Caroline
    Kelly, Joanna
    Yang, Yit
    Lotery, Andrew
    Williams, Michael
    Brazier, John
    PHARMACOECONOMICS, 2021, 39 (08) : 913 - 927
  • [42] Incremental Cost-Utility Ratio of Intravitreal Aflibercept Compared with Ranibizumab for the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion
    Cruess, Alan F.
    Jeddi, Mark
    Goeree, Ron
    Blackhouse, Gord
    Eriksson, Marianne
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [43] Branch and central retinal vein occlusion: clinical pearls from trials of ranibizumab
    Liu, Mimi
    Eichenbaum, David
    Taylor, Sarah
    Wang, Pin-wen
    Quezada-Ruiz, Carlos
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [44] Aflibercept: Newly Approved for the Treatment of Macular Edema Following Central Retinal Vein Occlusion
    Evoy, Kirk E.
    Abel, Steven R.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (06) : 819 - 827
  • [45] Clinical outcomes after switch from aflibercept to ranibizumab for macular edema secondary to retinal vein occlusion
    Wibbelsman, Turner D.
    Calem, Daniel B.
    Obeid, Anthony
    Mellen, Phoebe L.
    Konkoly, Michelle A.
    Velez, Michael R.
    Sioufi, Kareem
    Borkar, Durga S.
    Pandit, Ravi
    Klufas, Michael A.
    Hsu, Jason
    Regillo, Carl
    Ho, Allen C.
    Gupta, Omesh P.
    Spirn, Marc J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [46] A retrospective comparison of aflibercept and ranibizumab in the management of macular oedema secondary to retinal vein occlusion
    Di Simplicio, Sandro
    Hogg, Jeff
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [47] Intravitreal Ranibizumab Treatment for Macular Edema Associated with Central Retinal Vein Occlusion and Hemiretinal Vein Occlusion: Cases Reports
    Matias, Joao
    Matos, Rita
    OPHTHALMOLOGICA, 2014, 232 : 74 - 75
  • [48] 12-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
    Niedzwiecki, Mateusz
    Hunt, Adrian
    Nguyen, Vuong
    Mehta, Hemal
    Creuzot-Garcher, Catherine
    Gabrielle, Pierre-Henry
    Guillemin, Martin
    Fraser-Bell, Samantha
    Arnold, Jennifer
    McAllister, Ian L.
    Gillies, Mark
    Barthelmes, Daniel
    ACTA OPHTHALMOLOGICA, 2022, 100 (04) : E920 - E927
  • [49] Comment on: Ranibizumab and aflibercept intravitreal injection for treatment naive and refractory macular oedema in branch retinal vein occlusion
    Elkazza, Sumeia A.
    Hogg, H. D. Jeffry
    Di Simplicio, Sandro
    Dlay, Satnam S.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2022, 32 (01) : NP303 - NP304
  • [50] Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab
    Kerr Brogan
    Monica Precup
    Amanda Rodger
    David Young
    David Francis Gilmour
    BMC Ophthalmology, 18
12345